19 November 2026 | Thursday | News
Image Source: Public Domain
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced a collaboration with Grupo Fleury, one of Brazil's leading healthcare and diagnostic groups, with extensive laboratory infrastructure, scientific expertise and a strong presence across the Brazil healthcare ecosystem, to expand clinical trial operations in the country. Through the collaboration, Labcorp plans to launch local clinical trial kit assembly operations, followed by laboratory operations, helping sponsors conduct studies more efficiently while bringing services closer to research sites and patients across Brazil.
Labcorp's wholly owned central laboratory network spans North America, Europe, Asia and Africa. The collaboration with Grupo Fleury in Brazil expands Labcorp's clinical trial support capabilities across five continents. Brazil is a key destination for clinical research, supported by a diverse patient population and experienced investigators. The Grupo Fleury-supported new operations will provide sponsors with local support while maintaining the quality standards, scientific expertise and data consistency used across Labcorp's global network.
"Clinical trials today often span multiple countries, and sponsors need partners that can combine global expertise with local insight," said Brian Caveney, M.D., president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Our expansion in Brazil reflects the country's growing role in global clinical research while maintaining the high standards and consistency sponsors expect across global studies."
"Brazil continues to strengthen its position in global clinical research, supported by a diverse patient population, strong scientific capabilities and experienced research teams," said Edgar Rizzatti, president of Grupo Fleury's Medical, Technical, Hospitals, New Links and Innovation Business Unit. "By combining Grupo Fleury's scientific expertise, operational excellence and deep understanding of the local research environment with Labcorp's global clinical trial capabilities, we can help make clinical trials more efficient, broaden access to research opportunities and support the continued development of Brazil's clinical research ecosystem."
Local kit assembly is expected to begin in early 2027, while laboratory operations remain in development and are expected to launch by the end of 2027. Both operations will use Labcorp's global systems, processes and quality standards to support multinational clinical trials.
By establishing operations in Brazil, Labcorp expects to shorten kit delivery times, reduce reliance on international shipping and improve operational efficiency for clinical trial sponsors.
© 2026 Biopharma Boardroom. All Rights Reserved.